StemCells Revenue

Biotechnology Research • Newark, California, United States • 51-100 Employees

StemCells revenue & valuation

Annual revenue	$113,966
Revenue per employee	$2,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$364,691
Total funding	No funding

Key Contacts at StemCells

Socheata Sing

Director, Qa

Stan Tamaki

Director Of Antibody Research And Development

Venessa Lee

Quality Director

Martin Mcglynn

Ceo

Ferryadi Naibaho

Director Of Operations

Company overview

Headquarters	7707 Gateway Blvd., Suite 140, Newark, Cafilfornia 94560, US
Phone number	+19089385561
Website	stemcellsinc.com
NAICS	541714
SIC	873
Founded	1992
Employees	51-100
Socials

StemCells Email Formats

StemCells uses 1 email format. The most common is {last name} (e.g., doe@wisc.edu), used 100% of the time.

Format	Example	Percentage
{last name}	doe@wisc.edu	100%

About StemCells

StemCells, Inc. is currently engaged in clinical development of its HuCNS-SC® platform technology (purified human neural stem cells) as a potential treatment for both neurological and retinal disorders. Top-line data from the Company's Phase I/II clinical trial in thoracic spinal cord injury (SCI) showed measurable gains involving multiple sensory modalities and segments, including the conversion of two of seven patients enrolled in the study with complete injuries to incomplete injuries, post-transplant. The Company's Pathway™ Study, a Phase II proof-of-concept trial in cervical SCI is actively enrolling at eight sites and interim data from the first cohort of six patients is anticipated to be forthcoming in Q4 2015. StemCells, Inc. has also completed its Phase I/II clinical trial in GA-AMD. Top-line results from this study show a positive safety profile and favorable preliminary efficacy data related to visual acuity and contrast sensitivity. The Company's Radiant™ Study, a Phase II proof-of-concept trial in GA-AMD is now enrolling at the first of approximately twenty U.S. sites expected to participate. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company showed preliminary evidence of progressive and durable donor-derived myelination by MRI.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Senior

Employees by Department

StemCells has 23 employees across 9 departments.

Departments

Number of employees

Funding Data

StemCells has never raised funding before.

StemCells Tech Stack

Discover the technologies and tools that power StemCells's digital infrastructure, from frameworks to analytics platforms.

AWS Certificate Manager

SSL/TLS certificate authorities

Amazon Web Services

PaaS

HSTS

Security

Microsoft 365

Frequently asked questions

StemCells is located in Newark, California, US.

You can reach StemCells at +19089385561.

StemCells generates an estimated annual revenue of $113,966. This revenue figure reflects the company's market position and business performance in its industry.

StemCells has an estimated valuation of $364,691. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

StemCells was founded in 1992, making it 34 years old. The company has established itself as a significant player in its industry over this time.

StemCells has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.